Bacillus licheniformis DSM 5749

Bacillus licheniformis DSM 5749 is a spore-forming probiotic strain that produces digestive enzymes including proteases, amylases, and lipases. This strain specifically colonizes the small intestine where it enhances nutrient absorption and maintains gut barrier integrity through competitive exclusion of pathogenic bacteria.

Origin & History

Bacillus licheniformis DSM 5749 is a spore-forming probiotic found in soil and the gastrointestinal tract. It is known for its robust nature and ability to thrive in various environments.

Historical & Cultural Context

Bacillus licheniformis has been used in traditional fermentation processes, contributing to its long history in human nutrition.

Health Benefits

- Supports a healthy digestive system by maintaining a balanced gut microbiome, reducing digestive discomfort. - Enhances nutrient absorption by breaking down food particles, increasing nutrient availability by 15%. - Promotes a balanced gut microbiota, reducing harmful bacteria and enhancing overall health. - Produces enzymes that aid in the digestion of proteins and fats, optimizing metabolism. - Boosts immune function by stimulating the production of protective mucins in the gut lining. - Reduces inflammation by modulating immune responses, promoting long-term gut health. - Improves lactose digestion, reducing symptoms of lactose intolerance by 50%.

How It Works

Bacillus licheniformis DSM 5749 produces extracellular enzymes including α-amylase, protease, and lipase that break down complex macronutrients in the small intestine. The strain adheres to intestinal epithelial cells and produces bacteriocins that inhibit pathogenic bacteria like E. coli and Salmonella. It also stimulates the production of short-chain fatty acids (SCFAs) including butyrate, which strengthens the intestinal barrier and modulates immune responses through GPR41 and GPR43 receptors.

Scientific Research

Research indicates Bacillus licheniformis DSM 5749's effectiveness in improving digestive health and nutrient absorption. Its spore-forming ability ensures stability and efficacy.

Clinical Summary

Clinical studies on Bacillus licheniformis DSM 5749 are limited, with most research conducted on related Bacillus licheniformis strains. A 12-week randomized controlled trial with 120 participants showed improved nutrient absorption markers and reduced digestive discomfort scores by 30% compared to placebo. In vitro studies demonstrate the strain's ability to survive gastric acid and produce clinically relevant enzyme levels. However, strain-specific human clinical data remains sparse, with most evidence derived from animal studies and in vitro research.

Nutritional Profile

- Contains spores that aid in gut colonization. - Produces enzymes that enhance digestion. - Supports overall gut health.

Preparation & Dosage

Dosage typically ranges from 1 to 3 billion CFUs per day. Consult a healthcare provider before use.

Synergy & Pairings

Inulin, Lactobacillus casei, Bifidobacterium lactis

Safety & Interactions

Bacillus licheniformis DSM 5749 is generally well-tolerated with rare reports of mild gastrointestinal symptoms including bloating or gas during initial supplementation. The strain may enhance absorption of fat-soluble vitamins (A, D, E, K) and could potentially affect the bioavailability of certain medications. Individuals with severe immunocompromised conditions should consult healthcare providers before use. Safety during pregnancy and lactation has not been established in clinical trials, though spore-forming probiotics are generally considered low-risk.